American Heart Association’s 9 diet rules to lower heart disease risk
From childhood to adulthood, the AHA’s latest guidance shows how consistent, real-world food choices, not fad diets or…
All about new ‘triple-G’ drug that’s helped patients lose a quarter of their body weight
G whiz! The latest experimental GLP-1 from Eli Lilly isn’t just a diabetes drug — it also facilitates weight…
Fiber supplement stabilizes blood sugar in gestational diabetes
A simple fiber supplement could reshape the gut microbiome, stabilize blood sugar spikes, and even prevent preterm births…
Time-restricted eating improves hormone levels in women with PCOS
Polycystic ovary syndrome, or PCOS, affects as many as 18% of all childbearing-age women. The condition occurs when…
New analysis reveals flaws in traditional BMI classification system
Research from Italy to be presented at this year’s European Congress on Obesity (ECO 2026, Istanbul, Turkey, 12-15…
Hormonal contraception not associated with prevalence of idiopathic intracranial hypertension
Hormonal contraception, including birth control pills and intrauterine devices (IUDs), is not associated with an increased prevalence of…
New pathway enhances brown fat thermogenesis and metabolic health
Researchers have determined how a key protein activates brown fat by expanding blood vessels and nerves in the…
Wholegrain rye changes gut bacteria and lowers inflammation in obesity trial
A 12-week randomized trial found that wholegrain rye did not beat refined wheat for weight loss, but it…
Leaving home may worsen diet quality in young adults, Australian study finds
Moving out of the parental home may do more than change where young adults live; it may also…
Ozempic Goes Generic —But Not in the US
A drug that helped turn Novo Nordisk into Europe’s most valuable company is about to lose its…
GLP-1 RA generics have arrived. Could we buy semaglutide made for just $4?
Semaglutide is now generic. Just not in Australia. But in China, Brazil and Canada, generic drug makers are…
Semaglutide Falls Short in Alzheimer’s Phase 3 Trials
Phase 3 trials show oral semaglutide failed to slow early Alzheimer’s progression, potentially limiting its expansion beyond metabolic…